Literature DB >> 27678427

Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011-2012.

Nathan D Wong1, Daphnee Young2, Yanglu Zhao2, Huy Nguyen2, Jared Caballes2, Irfan Khan3, Robert J Sanchez4.   

Abstract

BACKGROUND: The 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline identifies 4 statin-eligible groups: (1) known atherosclerotic cardiovascular disease (ASCVD) aged ≥21 years, (2) low-density lipoprotein cholesterol (LDL-C) ≥ 190 mg/dL (4.9 mmol/L) aged ≥21 years, (3) diabetes mellitus aged 40 to 75 years with LDL-C 70 to 189 mg/dL (1.8-4.9 mmol/L), or (4) ≥7.5% 10-year ASCVD risk aged 40 to 75 years with LDL-C 70 to 189 mg/dL (1.8-4.9 mmol/L).
OBJECTIVES: We examined the number of statin-eligible US adults, statin use, LDL-C goal attainment, and adherence to lifestyle management.
METHODS: We identified subjects from the US National Health and Nutrition Examination Survey 2011-2012 in the 4 statin-eligible groups, proportion on statin, proportion at recommended LDL-C levels using National Lipid Association goals (<70 mg/dL [1.8 mmol/L] for very high risk and <100 mg/dL [2.6 mmol/L] for others), and adherence to lifestyle measures.
RESULTS: Of 5206 adults (representing 219 million), 1677 adults representing 62.6 million adults fit into 1 of the 4 statin-eligible groups. Statin use was 63.7% for the ASCVD, 61.4% for the LDL-C ≥ 190 mg/dL (4.9 mmol/L), 43.2% for the diabetes mellitus, and 27.2% for the 10-year risk ≥7.5% groups. Of those on statins with LDL-C measured, 79.7%, 98.0%, 42.3%, and 46.8% were not at LDL-C goal. Adherence to recommended <6% calories from saturated fat ranged from 3.3% to 6.4% and ≥40 minutes of physical activity ≥3 times a week from 54.7% to 65.1% across statin-eligible groups.
CONCLUSION: Many US adults eligible to receive statins based on American College of Cardiology/American Heart Association guidelines are not taking statins, and LDL-C levels still remain suboptimal.
Copyright © 2016 National Lipid Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cardiovascular disease; Cholesterol; Dyslipidemia; Goal attainment; Guidelines; Statins

Mesh:

Substances:

Year:  2016        PMID: 27678427     DOI: 10.1016/j.jacl.2016.06.011

Source DB:  PubMed          Journal:  J Clin Lipidol        ISSN: 1876-4789            Impact factor:   4.766


  23 in total

Review 1.  Advances in dyslipidemia management for prevention of atherosclerosis: PCSK9 monoclonal antibody therapy and beyond.

Authors:  Nathan D Wong; Paul D Rosenblit; Robert S Greenfield
Journal:  Cardiovasc Diagn Ther       Date:  2017-04

2.  Patterns and predictors of lipid-lowering therapy in patients with atherosclerotic cardiovascular disease and/or diabetes mellitus in 2014: Insights from a large US managed-care population.

Authors:  Dylan L Steen; Irfan Khan; Laura Becker; JoAnne M Foody; Katherine Gorcyca; Robert J Sanchez; Robert P Giugliano
Journal:  Clin Cardiol       Date:  2016-12-27       Impact factor: 2.882

3.  Racial and ethnic disparities due to Medicare Part D Star Ratings criteria among kidney transplant patients with diabetes, hypertension, and/or dyslipidemia.

Authors:  Marie A Chisholm-Burns; Christina A Spivey; Chi Chun Steve Tsang; Junling Wang
Journal:  J Manag Care Spec Pharm       Date:  2022-06

4.  A Cohort Analysis of Statin Treatment Patterns Among Small-Sized Primary Care Practices.

Authors:  Jingzhi Yu; Ann A Wang; Lindsay P Zimmerman; Yu Deng; Thanh-Huyen T Vu; Yacob G Tedla; Nicholas D Soulakis; Faraz S Ahmad; Abel N Kho
Journal:  J Gen Intern Med       Date:  2022-01-08       Impact factor: 6.473

5.  Communicating cardiovascular risk to high-risk cancer survivors: a mixed-methods pilot study of a statin risk communication tool.

Authors:  Nirupa J Raghunathan; Emily C Zabor; Nassim Anderson; Kevin Oeffinger; Emily S Tonorezos; Deborah Korenstein
Journal:  J Cancer Surviv       Date:  2020-02-10       Impact factor: 4.442

Review 6.  Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.

Authors:  Paul D Rosenblit
Journal:  Curr Diab Rep       Date:  2019-11-21       Impact factor: 4.810

7.  Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.

Authors:  Christopher P Cannon; Irfan Khan; Alexa C Klimchak; Matthew R Reynolds; Robert J Sanchez; William J Sasiela
Journal:  JAMA Cardiol       Date:  2017-09-01       Impact factor: 14.676

8.  US Antiarrhythmic Drug Treatment for Patients With Atrial Fibrillation: An Insurance Claims-Based Report.

Authors:  Jonathan G Tardos; Christopher J Ronk; Miraj Y Patel; Andrew Koren; Michael H Kim
Journal:  J Am Heart Assoc       Date:  2021-03-09       Impact factor: 5.501

9.  Budget Impact Analysis of PCSK9 Inhibitors for the Management of Adult Patients with Heterozygous Familial Hypercholesterolemia or Clinical Atherosclerotic Cardiovascular Disease.

Authors:  Usha G Mallya; Susan H Boklage; Andrew Koren; Thomas E Delea; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2018-01       Impact factor: 4.981

10.  Suboptimal control of lipid levels: results from the non-interventional Centralized Pan-Russian Survey of the Undertreatment of Hypercholesterolemia II (CEPHEUS II).

Authors:  Sergey Boytsov; Natalia Logunova; Yunona Khomitskaya
Journal:  Cardiovasc Diabetol       Date:  2017-12-16       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.